11 Feb 2022 16:43
REDX PHARMA PLC
("Redx" or "the Company")
Notice of Annual General Meeting
Alderley Park, 11 February 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that its Annual General Meeting will be held at 11am on 8 March 2022 at 85 Gresham Street, London EC2V 7NQ.
Following the announcement of preliminary results for the financial year ended 30 September 2021 on 27 January 2022, the Company announces that the Annual Report and Accounts and notice of Annual General Meeting have now been posted to shareholders. The Annual Report and Accounts and notice of Annual General Meeting are also available to view on Redx's website at www.redxpharma.com.
Shareholders are strongly encouraged to vote by proxy, appointing the Chair of the meeting, using the form of proxy distributed with the notice of meeting, to ensure their vote counts. The form of proxy is also available in the investor resources section of the Company's website: www.redxpharma.com.
Completed proxies should be returned to:
Equiniti
Aspect House
Spencer Road
Lancing
BN99 6DA
and must be received by 11am on 4 March 2022 to be valid.
The COVID-19 situation continues to evolve, and further announcements regarding the Annual General Meeting may be required in due course. The Company will seek to ensure that shareholders remain fully informed at all times.
For further information, please contact: |
|
|
|
Redx Pharma Plc
UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 |
US Office Peter Collum, Chief Financial Officer |
|
|
|
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
Matt Davis/ Adam Dawes |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
Claes Spång/ David Wilson/ Satheesh Nadarajah |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
Rupert Dearden/ Freddy Crossley/ Emma Earl |
|
|
|
FTI Consulting | T: +44 (0)203 727 1000 |
Simon Conway/ Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/